Correlation and Expression of ER, PR, HER-2/Neu and Its Association with Clinicopathological Variables in Invasive Ductal Carcinoma of Breast
DOI:
https://doi.org/10.21276/apalm.3374Keywords:
Invasive Ductal Carcinoma Breast, Estrogen Receptors, Progesterone Receptor, Her-2/Neu, c-erbB-2 Proto-OncogeneAbstract
Background: Invasive ductal carcinoma (IDC) of the breast is the largest group of malignant mammary tumors, comprising approximately 75% of mammary carcinomas. The prognosis of breast cancer depends on the histological type, size of the tumor, tumor necrosis, skin, nipple, and chest wall invasion, lymphovascular invasion, grade, stage, and the status of estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2. These factors are especially important in planning therapy and for clinical follow-up.
Materials and Methods: A total of 114 cases with IDC who underwent modified radical mastectomy and were diagnosed as malignant on histopathology were collected from the Department of Pathology from January 2022 to January 2024. Immunohistochemistry (IHC) for ER, PR, and HER-2 status was evaluated by histopathologists following the College of American Pathologists (CAP) guidelines. Statistical analysis was performed using SPSS software versions 21 and 23 for Windows, with the chi-square test and Pearson correlation test used to determine the quantitative data.
Results: Our results showed that most of the breast cancer patients (53.6%) were aged 50 and above. The mean age of the patients was 51.1 ± 2.3 years (ranging from 30 to 75 years). Forty-six (40.4%) and 30 (26.3%) cases were positive for ER and PgR, respectively, and 24 cases (21.1%) were positive for HER-2. We also observed a significant positive correlation between ER and PR expression (P = 0.00), and they inversely correlated with HER-2/neu expression (P = 0.02).
Conclusion: The ER/PR/HER2 subtyping is simple, inexpensive, easy to interpret, reliable, reproducible, and readily available for clinicians without additional tests. It provides valuable prognostic information for making the best therapeutic decisions.
References
Nikbakhsh N, Ghaemian N. Original article. Iran J Pathol. 2015;10(3):221–6.
Sohail SK, Sarfraz R, Imran M, Kamran M. Estrogen and progesterone receptor expression in breast carcinoma and its association with clinicopathological variables among the Pakistani population. Cureus. 2020;12(8)
Alsughayer AM, Dabbagh TZ, Abdel-razeq RH, Al-jussani GN. Changing trends in estrogen receptors/progesterone receptors/HER2 prevalence rates among Jordanian patients with breast cancer over the years. Breast Cancer Res Treat. 2022;1–8.
Kwak Y, Jang SY, Choi JY, Lee H, Shin DS, Park YH, et al. Progesterone receptor expression level predicts prognosis of estrogen receptor-positive/HER2-negative young breast cancer: a single-center prospective cohort study. Cancers (Basel). 2023;15(3435)
Iqbal BM, Buch A. Hormone receptor (ER, PR, HER2/neu) status and proliferation index marker (Ki-67) in breast cancers: their onco-pathological correlation, shortcomings and future trends. Indian J Pathol Oncol. 2016;7:12–8.
Parise CA, Caggiano V. Breast cancer survival defined by the ER/PR/HER2 subtypes and a surrogate classification according to tumor grade and immunohistochemical biomarkers. Breast Cancer Res. 2014;16(1):202.
Dunnwald LK, Rossing MA, Li CI. Hormone receptor status, tumor characteristics, and prognosis: a prospective cohort of breast cancer patients. Breast Cancer Res. 2007;9(1)
Aitken SJ, Thomas JS, Langdon SP, Harrison DJ, Faratian D. Quantitative analysis of changes in ER, PR and HER2 expression in primary breast cancer and paired nodal metastases. Ann Oncol. 2010;21(6):1254–61.
Nabi MG, Ahangar A, Kaneez S. Estrogen receptors, progesterone receptors and their correlation with respect to HER-2/neu status, histological grade, size of lesion, lymph node metastasis, lymphovascular involvement and age in breast cancer patients in a hospital in North India. Ann Oncol. 2016;7(23):1–7.
Dayal A, Shah RJ, Kothari S, Patel SM. Correlation of HER-2/neu status with estrogen, progesterone receptors and histologic features in breast carcinoma. Indian J Pathol Oncol. 2016;2(1):18–24.
Asif HM, Sultana S, Akhtar N, Rehman JU, Rehman RU. Prevalence, risk factors and disease knowledge of breast cancer in Pakistan. Asian Pac J Cancer Prev. 2014;15(11):4411–6.
Vedashree MK, Rajalakshmi V. Clinico-pathological study of breast carcinoma with correlation to hormone receptor status & HER2/neu. Indian J Pathol Oncol. 2016;3(4):690–5.
Khalid M, Shah SIH, Javaid M, Nadeem K, Kanwal T. Frequency of estrogen and progesterone receptor status in breast cancer patients: a single institutional experience. Ann Punjab Med Coll. 2013;7(1):6–9.
Zeeshan S, Ali B, Ahmad K, Chagpar S, Sattar AK. Clinicopathological features of young versus older patients with breast cancer at a single Pakistani institution and a comparison with a national US database. J Glob Oncol. 2019;5:1–6.
Patnayak R, Jena A, Rukmangadha N, Chowhan AK, Sambasivaiah K, Phaneendra BV, et al. Hormone receptor status (estrogen receptor, progesterone receptor), human epidermal growth factor-2 and p53 in South Indian breast cancer patients: a tertiary care center experience. Indian J Med Paediatr Oncol. 2015;36(3):117–22.
Mahmood H, Faheem M, Mahmood S, Sadiq M, Irfan J. Impact of age, tumor size, lymph node metastasis, stage, receptor status and menopausal status on overall survival of breast cancer patients in Pakistan. Asian Pac J Cancer Prev. 2015;16(3):1019–24.
Hathila TN, Sangle RB, Doshi SA, Firdaus DA, Rupani MP. A prospective study of estrogen, progesterone and HER2/neu receptor in cases of breast cancer in a tertiary care hospital of Bhavnagar, Gujarat, Western India. Natl J Med Res. 2015;5(3):185–9.
Shrigondekar P, Desai S, Bhosale S, Mankar D, Badwe A. Study of hormone receptor status of breast carcinoma and its correlation with the established prognostic markers. Int J Health Sci Res. 2012;2(3):109–16.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Deepthi Chandrika Chintalapudi, Bindu Madhavi Rajulapati, Satya Prakash Turlapati
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access at http://opcit.eprints.org/oacitation-biblio.html).
